Mainz Biomed (NASDAQ:MYNZ) Trading 2.7% Higher – Should You Buy?

Mainz Biomed NV (NASDAQ:MYNZ) was up 2.7% on Tuesday . The company traded as high as $1.23 and last traded at $1.15. Approximately 188,970 shares traded hands during mid-day trading, an increase of 4% from the average daily volume of 182,289 shares. The stock had previously closed at $1.12.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Mainz Biomed in a research report on Monday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mainz Biomed has an average rating of “Hold” and a consensus price target of $14.00.

Mainz Biomed Stock Performance

The stock has a market capitalization of $9.87 million, a P/E ratio of -0.02 and a beta of 0.27. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $1.26 and a two-hundred day moving average price of $1.52.

Mainz Biomed (NASDAQ:MYNZ) last released its earnings results on Friday, September 26th. The company reported ($1.32) EPS for the quarter. The company had revenue of $0.14 million during the quarter. On average, equities analysts forecast that Mainz Biomed NV will post -23.6 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Mainz Biomed stock. Armistice Capital LLC raised its stake in Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 285,000 shares of the company’s stock after purchasing an additional 88,400 shares during the period. Armistice Capital LLC owned 6.23% of Mainz Biomed worth $402,000 as of its most recent SEC filing.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.